GUIDELINE UPDATES
The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 genotypes and the dosing of voriconazole is published in full on http://www.pharmgkb.org and https://cpicpgx.org/guidelines/. Relevant information will be reviewed periodically and updated guidelines published online.
LITERATURE REVIEW
We searched the PubMed® database (1966 to May 2016) for the following keywords:
(cytochrome P450 2C19 or CYP2C19) AND (voriconazole). Using these search terms, 134 publications were identified. In addition, studies annotated in PharmGKB (http://www.pharmgkb.org) were identified. Study inclusion criteria included publications that included analyses for the association between CYP2C19 genotypes and metabolism of voriconazole or voriconazole-related adverse drug events or clinical outcomes. Non-English manuscripts were excluded. Following application of these inclusion criteria, 35 publications were reviewed and included in the evidence table (Supplemental Table S1 ).
The CYP2C19 frequency table (1) include updates of those previously published in CPIC guidelines (2) (3) (4) (5) . Updates to the CYP2C19 frequency tables were made by searching the PubMed® database (1995 to 2015). The following criteria were used for CYP2C19: (CYP2C19 or 2C19 or cytochrome P4502C19) AND (genotype OR allele OR frequency OR minor allele OR variant OR ethnic OR race OR racial OR ethnicity) with filter limits set to retrieve "full-text" and "English" literature. In addition, reports were also identified from citations by others or review articles. Studies were considered for inclusion in the CYP2C19 frequency table if: (1) the ethnicity of the population was clearly indicated, (2) either allele frequencies or genotype frequencies were reported, (3) the method by which the genes were genotyped was indicated, (4) the sample population consisted of at least 50 individuals with a few exceptions (e.g., smaller cohorts that were part of larger studies) and (5) the study represented an original publication (no reviews or meta-analyses). Diplotype and phenotype frequencies were estimated using the equation describing Hardy Weinberg equilibrium based on reported allele frequencies.
GENES: CYP2C19

Genetic Test Interpretation
CYP2C19 genetic variants are typically reported as haplotypes, which are defined by a specific combination of single nucleotide polymorphisms (SNPs) and/or other sequence variants including insertions and deletions that are interrogated during genotyping analysis. CYP2C19 haplotypes are assigned a star-allele (*) nomenclature to allow for the standardization of genetic polymorphism annotation (6). A complete list of CYP2C19 star-allele nomenclature along with the genetic variants that define each star-allele is available at http://www.cypalleles.ki.se/cyp2c19.htm, respectively. Information regarding CYP2C19 haplotypes (star-alleles) is also available at PharmGKB (www.pharmgkb.org). Knowing which SNPs or other genetic variants a particular test interrogates is important as the inclusion or exclusion of certain genetic variants in a pharmacogenetic test could affect the reported starallele result.
Reference laboratories usually report a diplotype, which is the summary of inherited maternal and paternal star-alleles (e.g. CYP2C19*1/*2, where an individual inherited a *1 allele and a *2 allele). Commonly reported CYP2C19 star-alleles are categorized into functional groups (e.g., normal function, decreased function, or no function) based on the predicted activity of the encoded enzyme (CYP2C19 allele definition Limited data are available to assess the predicted phenotypes for rare CYP2C19 diplotype combinations that include CYP2C19 alleles with decreased function and that have low frequencies in the general population (e.g., *9, *10). Therefore, for the purpose of this guideline the following assignments have been proposed: patients with two decreased function alleles OR patients with one normal/increased function allele AND one decreased function allele are categorized as "likely intermediate metabolizers" (e.g., CYP2C19*1/*9, *9/*9, *9/*17) and patients with one decreased function allele and one no function allele are categorized as "likely poor metabolizers" (CYP2C19*2/*9). For many rare alleles, no information regarding enzyme activity is currently available, and those with functional data have only been determined by in vitro studies. Consequently, the proposed "likely intermediate" and "likely poor" metabolizer assignments were developed for diplotypes that contain one allele with an established effect on enzyme activity and a second allele with limited or no available activity data. The diplotypes in these new categories may be revised as new data become available, which will be updated on cpicpgx.org and www.pharmgkb.org as needed.
Available Genetic Test Options
Commercially available genetic testing options change over time. Additional information about pharmacogenetic testing can be found at http://www.pharmgkb.org or the Genetic Testing Clinical laboratories may analyze for different SNPs or other genetic variants, which are dependent on the genotyping platforms used and may affect the reported diplotype leading to discrepant results between methodologies. Therefore, it is important to not only know the alleles interrogated by each laboratory, but also which sequence variants (e.g., SNPs, insertions, deletions) are tested and how copy number variants are reported. Clinical laboratories commonly
give an interpretation of the genotype result and provide a predicted phenotype. Phenotype assignment for this guideline is defined in the main manuscript and supplementary data, but may differ from some clinical laboratory interpretations. Any CYP2C19 genotyping results used to guide patient pharmacotherapy and/or deposited into patient medical records should be derived from validated genotyping platforms in clinical laboratories that implement the appropriate regulatory standards and best practices (e.g., CAP, CLIA).
CYP2C19 Other Consideration
There are several factors to consider when genotyping CYP2C19. Some of these factors may DMET) analyze over 15 CYP2C19 star-alleles, some of which are rare and not well characterized. Therefore, uncertainty exists when translating a genotype result into a predicted CYP2C19 phenotype in instances where a patient is found to carry a poorly characterized allele.
Bioinformatics tools such as Polyphen-2 and Sorting Tolerant From Intolerant (SIFT) algorithms computationally predict the effect of sequence variations found in rare and poorly characterized alleles on CYP2C19 enzymatic function (13) and may assist in diplotype interpretation in instances where a poorly characterized allele is reported. However, these in silico methods are not a substitute for in vitro and in vivo analyses.
LEVELS OF EVIDENCE LINKING GENOTYPE TO PHENOTYPE
The evidence summarized in Supplemental Tables S1 is graded (14) on a scale of high, moderate, and weak, based upon the level of evidence:
High: Evidence includes consistent results from well-designed, well-conducted studies. Overall, the therapeutic recommendations are simplified to allow rapid interpretation by clinicians. CPIC uses a slight modification of a transparent and simple system for just three categories for recommendations adopted from the rating scale for evidence-based recommendations on the use of retroviral agents (15): 'strong', where "the evidence is high quality and the desirable effects clearly outweigh the undesirable effects"; 'moderate', in which "there is a close or uncertain balance" as to whether the evidence is high quality and the desirable clearly outweigh the undesirable effects; and 'optional', in which the desirable effects are closely balanced with undesirable effects and there is room for differences in opinion as to the need for the recommended course of action.
RESOURCES TO INCORPORATE PHARMACOGENETICS INTO AN ELECTRONIC HEALTH RECORD WITH CLINICAL DECISION SUPPORT
Clinical decision support (CDS) tools integrated within electronic health records (EHRs) can help guide clinical pharmacogenetics at the point of care (16-20). See
https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/ for resources to support the adoption of CPIC guidelines within an EHR. Based on the capabilities of various EHRs and local preferences, we recognize that approaches may vary across organizations. Our intent is to synthesize foundational knowledge that provides a common starting point for incorporating the use of CYP2D6 and/or CYP2C19 genotype results to guide TCA dosing in an EHR.
Effectively incorporating pharmacogenetic information into an EHR to optimize drug therapy should have some key attributes. Pharmacogenetic results, an interpreted phenotype, and a concise interpretation or summary of the result must be documented in the EHR (21, 22) . To incorporate a phenotype in the EHR in a standardized manner, genotype test results provided by the laboratory must be consistently translated into an interpreted phenotype ( Table 1 , main manuscript). Because clinicians must be able to easily find the information, the interpreted phenotype may be documented as a problem list entry or in a patient summary section; these phenotypes are best stored in the EHR at the "person level" rather than at the date-centric "encounter level". Additionally, results should be entered as standardized and discrete terms to facilitate using them to provide point-of-care CDS (16, 23).
Because pharmacogenetic results have lifetime implications and clinical significance, results
should be placed into a section of the EHR that is accessible independent of the test result date to allow clinicians to quickly find the result at any time after it is initially placed in the EHR. To facilitate this process, CPIC is providing gene-specific information figures and tables that include full diplotype to phenotype tables, diagram(s) that illustrate how CYP2D6 and/or CYP2C19 pharmacogenetic test results could be entered into an EHR, example EHR consultation/genetic test interpretation language and widely used nomenclature systems for genes relevant to the CPIC guideline (see https://www.pharmgkb.org/page/cyp2c19RefMaterials) (24) .
Point-of-care CDS should be designed to effectively notify clinicians of prescribing implications at any time after the test result is entered into the EHR. CPIC is also providing gene-drug specific tables that provide guidance to achieve these objectives with diagrams that illustrate how point-of-care CDS should be entered into the EHR, example pre-and post-test alert language, and widely used nomenclature systems for drugs relevant to the CPIC guideline (see https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/). 
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